GLYCOPYRROLATE

Search structure


Trade Names:	CUVPOSA GLYCOPYRROLATE GLYRX-PF LONHALA MAGNAIR KIT ROBINUL ROBINUL FORTE SEEBRI
Status:	Approved (1961)
Entry Type:	Small molecule
Molecule Category:	Parent
UNII:	V92SO9WP2I

Structure


InChI Key	VPNYRYCIDCJBOM-UHFFFAOYSA-M
Smile	C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]
InChI	InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C19H28BrNO3
Molecular Weight	398.34
AlogP	2.46
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	46.53
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	23.0

Pharmacology

	Primary Target
M₁ receptor
M₂ receptor
M₃ receptor
M₄ receptor
M₅ receptor

Indications

Mesh Heading	Maximum Phase	Reference
Pulmonary Disease, Chronic Obstructive	Phase 2	ClinicalTrials
Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive	Phase 1/Phase 2	ClinicalTrials
Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms	Phase 4	ClinicalTrials
Parkinson Disease; Sialorrhea	Phase 2	ClinicalTrials
Depression; Hyperhidrosis	Phase 1	ClinicalTrials
Hypotension	Phase 4	ClinicalTrials
Sialorrhea	Phase 1/Phase 2	ClinicalTrials
Paralysis	Phase 4	ClinicalTrials
Burns	Phase 3	ClinicalTrials
Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive	Phase 2	ClinicalTrials
Cholecystolithiasis; Cholelithiasis; Gallstones	Phase 4	ClinicalTrials
Coronary Artery Disease	Phase 4	ClinicalTrials
Nausea; Vomiting	Phase 4	ClinicalTrials

Related Entries

MCS

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend :

Indication

Mechanism of Action

Primary Target

Target Level

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Mixture

Mixture

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Gastrointestinal disorders Dry mouth	40.0
Gastrointestinal disorders Vomiting	40.0
Gastrointestinal disorders Constipation	35.0
General disorders and administration site conditions Flushing	30.0
Respiratory, thoracic and mediastinal disorders Nasal congestion	30.0
Gastrointestinal disorders Constipation
General disorders and administration site conditions Flushing
Nervous system disorders Headache	15.0
Infections and infestations Sinusitis	15.0
Infections and infestations Upper respiratory tract infection	15.0
Renal and urinary disorders Urinary retention	15.0
Gastrointestinal disorders Dry mouth
Respiratory, thoracic and mediastinal disorders Nasal congestion
Gastrointestinal disorders Vomiting
Nervous system disorders Headache
Infections and infestations Sinusitis
Gastrointestinal disorders Dry mouth	2.4

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Respiratory, thoracic and mediastinal disorders	25.78
General disorders and administration site conditions	12.08
Cardiac disorders	9.36
Nervous system disorders	6.87
Investigations	5.9
Injury, poisoning and procedural complications	5.49
Gastrointestinal disorders	5.06
Infections and infestations	4.7
Psychiatric disorders	4.02
Immune system disorders	3.76
Musculoskeletal and connective tissue disorders	3.51
Vascular disorders	3.42
Skin and subcutaneous tissue disorders	2.83

Cross References

Resources	Reference
ChEBI	90972
ChEMBL	CHEMBL1201027
DrugBank	DB00986
EPA CompTox	DTXSID6023109
FDA SRS	V92SO9WP2I
Guide to Pharmacology	7459
PubChem	11693
SureChEMBL	SCHEMBL41436
ZINC	ZINC00968301

CONTENTS